-
Following FDA’s Action, Novartis’ Zelnorm Gets Recall Order From Chinese Drug Regulator
China’s State Food & Drug Administration Says Zelnorm Side Effect Risks Outweigh This Drug’s Benefits (Posted by Tom Lamb at DrugInjuryWatch.com) A June 8, 2007 Associated Press (AP) article published in The Washington Post…
-
Emerging Drug Safety Issue Regarding Abbott’s TriCor Triglycerides Medication
Barron’s June 2007 Report: Experts Are Concerned That TriCor May Cause Decline In Kidney Functions (Posted by Tom Lamb at DrugInjuryWatch.com) The weekly business newspaper Barron’s reported on June 3, 2007 that some expert…
-
Novartis Ordered To Recall Zelnorm From Market In Switzerland
Swiss Pharmaceutical Regulator States That Side Effect Risks Outweigh Benefits (Posted by Tom Lamb at DrugInjuryWatch.com) In a brief June 1, 2007 Wall Street Journal (WSJ) article it was reported that Switzerland’s pharmaceuticals regulator…
-
February 2007 Verdict In Hormone Replacement Therapy Trial Overturned in Favor of Wyeth
Court Grants Drug Company’s Motion To Set Aside Philadelphia Jury Verdict In Nelson v. Wyeth Lawsuit (Posted by Tom Lamb at DrugInjuryWatch.com) On May 31, 2007 Wyeth announced that the Philadelphia Court of Common…
-
Verdict For Plaintiff McCarrell In New Jersey Accutane Trial
Jury Awards $2.6 Million For Inflammatory Bowel Disease Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com)_____________________________________________________________________ Update: Accutane Retrial Verdict: Roche Ordered to Pay $25 Million to Accutane User By David Voreacos and John…
-
The Avandia Heart Attack Risk Was Raised To FDA Back In 2000; Will Agency Wait Until 2009 To Act?
In Comparison, Europe’s Regulators Had Glaxo Change Avandia Label In 2006 To Include Warning About Risk Of Cardiac Ischemic Events Such As Heart Attacks (Posted by Tom Lamb at DrugInjuryWatch.com) In a May 24,…
